This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva sees publication of decision, report in Copaxone dominance-abuse case

( January 20, 2025, 11:26 GMT | Official Statement) -- MLex Summary: The European Commission today released a summary version of its decision last year to fine Teva Pharmaceuticals more than 462 million euros for abusing the patent system to protect Copaxone, its blockbuster multiple sclerosis drug. In October, Teva was also sanctioned for spreading misleading information about a rival drug's safety and therapeutic equivalence with Copaxone, to hinder its market entry.The summary version of the decision and the hearing officer's report are attached. Case reference is AT.40588. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections